Will Dendreon Break FDA and Wall Street Stranglehold on Cancer?

Tomorrow, April 28, 2009, at long last the day of reckoning for Immunotherapy is upon us. Dendreon will present its statistically significant Impact trial results on Provenge at the American Urological...

Prostate Cancer History Was Made Today!

A non toxic, non invasive Immunotherapy to strengthen the body’s ability to fight prostate cancer achieved its goal of being  supportive of the previous trials, as required by the FDA. Mitchell Gold,...